Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Guaraldi

Showing results (81-90 of 85) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 85 results.
International Journal of STD & AIDS|July 31, 2012
Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factorsR Bucciardini, G D'Ettorre, S Baroncelli, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 19, 2011
Adverse outcome analyses of observational data: assessing cardiovascular risk in HIV diseaseV A Triant, F Josephson, C G Rochester, et al.
HIV Medicine|March 4, 2024
SARS-CoV-2 testing, positivity, and factors associated with COVID-19 among people with HIV across Europe in the multinational EuroSIDA cohortO Fursa, W Bannister, B Neesgaard, et al.
Infection|June 15, 2007
First Italian consensus statement on diagnosis, prevention and treatment of cardiovascular complications in HIV-infected patients in the HAART era (2006)G Carosi, E Quiros-Roldan, C Torti, et al.
HIV Medicine|October 25, 2019
The EuroSIDA study: 25 years of scientific achievementsK Laut, O Kirk, J Rockstroh, et al.
Pageof 9

Showing results (81-90 of 85) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 85 results.
International Journal of STD & AIDS|July 31, 2012
Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factorsR Bucciardini, G D'Ettorre, S Baroncelli, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 19, 2011
Adverse outcome analyses of observational data: assessing cardiovascular risk in HIV diseaseV A Triant, F Josephson, C G Rochester, et al.
HIV Medicine|March 4, 2024
SARS-CoV-2 testing, positivity, and factors associated with COVID-19 among people with HIV across Europe in the multinational EuroSIDA cohortO Fursa, W Bannister, B Neesgaard, et al.
Infection|June 15, 2007
First Italian consensus statement on diagnosis, prevention and treatment of cardiovascular complications in HIV-infected patients in the HAART era (2006)G Carosi, E Quiros-Roldan, C Torti, et al.
HIV Medicine|October 25, 2019
The EuroSIDA study: 25 years of scientific achievementsK Laut, O Kirk, J Rockstroh, et al.
Pageof 9